• August 4, 2022

  EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

• August 3, 2022

  Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

• July 26, 2022

  EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT

• July 26, 2022

  EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

• July 25, 2022

  AΒ-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE

View All

• August 8, 2022

  IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2023 [Material, Webcast]”

• August 5, 2022

  IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2023”

• June 17, 2022

  IR "Notice of Resolution of the 110th Ordinary General Meeting of Shareholders"

• May 24, 2022

  IR “Notice of Convocation of the 110th Ordinary General Meeting of Shareholders”

• May 16, 2022

  IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2022 [Material, Webcast]”

View All

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

View All